Literature DB >> 2572206

Risk factors for neuroleptic malignant syndrome. A case-control study.

P E Keck1, H G Pope, B M Cohen, S L McElroy, A A Nierenberg.   

Abstract

A number of risk factors have been proposed for the development of neuroleptic malignant syndrome, but these have not been subjected to controlled study. To address this problem, we performed a case-control study comparing 18 patients with neuroleptic malignant syndrome and 36 matched neuroleptic-treated control patients with no known history of the syndrome to identify potential risk factors. Patients with neuroleptic malignant syndrome displayed significantly greater psychomotor agitation, received significantly higher doses of neuroleptics at greater rates of dosage increase, and received a greater number of intramuscular injections than controls.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2572206     DOI: 10.1001/archpsyc.1989.01810100056011

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  47 in total

Review 1.  Psychiatry.

Authors:  K Granville-Grossman
Journal:  Postgrad Med J       Date:  1990-09       Impact factor: 2.401

Review 2.  Neuroleptic malignant syndrome: a neuroimmunologic hypothesis.

Authors:  Rebecca E Anglin; Patricia I Rosebush; Michael F Mazurek
Journal:  CMAJ       Date:  2010-08-09       Impact factor: 8.262

Review 3.  Neuroleptic malignant syndrome--follow-up study.

Authors:  P Buckley; A Freyne; A McCarthy; C Larkin
Journal:  Ir J Med Sci       Date:  1991-02       Impact factor: 1.568

4.  The fallacy of the medical model and the dangers of psychotropic drugs as a mode of treatment for mental disorders.

Authors:  V D Sanua
Journal:  J Prim Prev       Date:  1996-09

5.  Early detection of an atypical presentation of neuroleptic malignant syndrome: A case report.

Authors:  P Brittany Vickery; Lindsy Meadowcraft; Stephen B Vickery
Journal:  Ment Health Clin       Date:  2018-03-23

6.  Neuroleptic malignant syndrome with metoclopramide overdose coexisting with Clostridium difficile diarrhea.

Authors:  Azhar Supariwala; Gunjan Kant; Raymonde E Jean
Journal:  Intensive Care Med       Date:  2011-06-18       Impact factor: 17.440

7.  Risk factors in neuroleptic malignant syndrome.

Authors:  Vinay Gupta; Rakesh Magon; B P Mishra; G B S Sidhu; Ranjiv Mahajan
Journal:  Indian J Psychiatry       Date:  2003-01       Impact factor: 1.759

8.  A naturalistic comparison of the efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in agitated elderly patients with schizophrenia.

Authors:  Hidenobu Suzuki; Keishi Gen; Yuki Takahashi
Journal:  Ther Adv Psychopharmacol       Date:  2013-12

Review 9.  Pitfalls and problems of the long term use of neuroleptic drugs in schizophrenia.

Authors:  M F Bristow; S R Hirsch
Journal:  Drug Saf       Date:  1993-02       Impact factor: 5.606

10.  Prevalence of neuroleptic malignant syndrome in 672 consecutive male in-patients.

Authors:  Pradyot Sarkar; Chandrashekhar Natarajan; Neeta Gode
Journal:  Indian J Psychiatry       Date:  2009 Jul-Sep       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.